Search…

Tianshili (600535.SH) subsidiary TSL2109 capsule receives approval notice for drug clinical trial.

24/09/2025

Wisdom Financial News App, Tasly (600535.SH) announced that recently, the company's wholly-owned subsidiary Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi") received the National Medical Products Administration's approval to issue the "Notice of Approval for Clinical Trials of TSL2109 Capsules for Advanced Solid Tumors".

Latest

1 m ago

After the night futures market opened, glass, fuel, Shanghai copper, international copper, soybean meal, and palm oil all rose by more than 1%, while PTA, soda ash, pulp, and crude oil also saw increases.

1 m ago

Xuguang New Energy Obtains 0BB Battery Testing Patent, Blue Wealth Biochemical Holdings' Layout Shows Results

1 m ago

$100,000 H-1B fees impact the financial industry, with JPMorgan Chase (JPM.US) being the hardest hit.

1 m ago

Statement: Eight international oil companies operating in the Kurdistan region of Iraq have reached a principle agreement with the Baghdad government and the Kurdish regional government to resume oil exports.

2 m ago

Deputy Secretary of Shunyi District Committee and District Mayor Cui Xiaohao conducted a special research on the "Thirteenth Five-Year Plan" for promoting the high-quality development of the intelligent equipment industry economy.

See all latest